Open label, single center pilot proof of concept study to assess a combination of orlistat, simethicome and activated charcoal in ameliorating the gastrointestinal adverse effects compared to orlistat taken alone as a single medication
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Orlistat (Primary) ; Charcoal; Simethicone
- Indications Obesity
- Focus Proof of concept; Therapeutic Use
- 01 Aug 2017 According to Callitas Therapeutics media release, M Pharmaceutical changed its name to Callitas Therapeutics
- 20 Sep 2016 New trial record
- 29 Aug 2016 Results published in M Pharmaceutical media release.